Enzo Biochem (NYSE:ENZ) released its quarterly earnings data on Thursday. The medical research company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01), Bloomberg Earnings reports. Enzo Biochem had a negative return on equity of 2.83% and a negative net margin of 2.32%.

Enzo Biochem (NYSE:ENZ) opened at $9.51 on Friday. Enzo Biochem has a 52 week low of $6.27 and a 52 week high of $12.04.

In related news, Director Gregory M. Bortz sold 42,005 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $9.82, for a total transaction of $412,489.10. Following the sale, the director now directly owns 292,875 shares in the company, valued at approximately $2,876,032.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP James Michael O’brien sold 22,866 shares of the firm’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $10.28, for a total value of $235,062.48. Following the sale, the executive vice president now owns 34,886 shares in the company, valued at $358,628.08. The disclosure for this sale can be found here. Insiders sold a total of 191,398 shares of company stock worth $1,925,292 over the last ninety days. Corporate insiders own 8.90% of the company’s stock.

Several equities analysts have recently weighed in on ENZ shares. Zacks Investment Research lowered Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. BidaskClub lowered Enzo Biochem from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, TheStreet lowered Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/08/enzo-biochem-enz-releases-quarterly-earnings-results-hits-estimates.html.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Earnings History for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.